Behind the paper

Share the story behind your paper, from conception to publication, the highs and the lows

A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent anti-tumor response

The type 1 NKT cell stimulating glycolipid α-galactosylceramide (α-GalCer) was first identified by the Pharmaceutical Research Laboratory of Kirin Brewery in a screen for novel anti-tumor agents. Based on promising preclinical data it was tested as an anticancer drug in multiple clinical studies.
Go to the profile of Jamie Rossjohn +1
Jamie Rossjohn and 1 other
Nov 23, 2020